Announcements

Clinuvel's company releases, including archives.

Friday, 30 January 2015 19:27

Appendix 4C - Q2 FY15

Friday, 23 January 2015 18:36

Appendix 3Y - January 23

Friday, 23 January 2015 18:35

Appendix 3B - January 23

Wednesday, 21 January 2015 17:47

Appendix 3X - Mr Willem Blijdorp

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is pleased to announce the appointment of Mr Willem Blijdorp as a Non-Executive Director of the Company. Mr Blijdorp’s appointment comes as Clinuvel prepares the commercial distribution of SCENESSE® for the rare disease erythropoietic protoporphyria (EPP) throughout the European Union. Mr Blijdorp is the founding member, majority shareholder and a current supervisory Director of B&S International NV, a privately owned Dutch group focused on the wholesale and international trading of luxury and fast moving consumer goods and pharmaceutical products. He managed B&S International for 27 years as CEO and remains actively…
Tuesday, 23 December 2014 10:38

European Commission approves SCENESSE®

Commercial distribution in preparation for European EPP patients Clinuvel Pharmaceuticals Ltd (ASX:CUV; XETRA-DAX: UR9; ADR: CLVLY) announced today that the European Commission has ratified the recommendation of the European Medicines Agency (EMA), granting marketing approval under exceptional circumstances to Clinuvel’s breakthrough drug SCENESSE® (afamelanotide 16mg). Clinuvel is now allowed to market SCENESSE® for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP) across the 31 EMA counties1. EPP is defined as the most severe clinical form of light and sunlight intolerance, often described as anaphylaxis to indoor and outdoor light sources. EPP patients are characterised by a lifelong…
Tuesday, 23 December 2014 08:47

Appendix 3Y - December 23 2014

Tuesday, 23 December 2014 08:46

Appendix 3B - December 23 2014

Italian, Swiss expert centres report "good clinical effectiveness and good safety" of drug in rare disease prior to broader access across Europe Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that long term observational data from the use of its first-in-class drug SCENESSE® (afamelanotide 16mg) in the rare disease erythropoietic protoporphyria (EPP) have been e-published in the British Journal of Dermatology. Two expert porphyria centres – the San Gallicano Dermatological Institute in Rome and the Triemli Municipal Hospital in Zurich – have reported on the use of SCENESSE® in 115 adult EPP patients treated for up to…
Friday, 05 December 2014 12:59

Form 604 - December 5, 2014

Page 1 of 37

Share Price

Buy : 3.68

Sell : 3.75

First : 3.75

Last : 3.75

High : 3.75

Low : 3.67

ASX: CUV 20 mins delay.

Volume : 6,704 Trades: 28

Last Traded : 30-Jan-2015 16:10:22

Popular Articles

Investor Spotlight

Clinuvel Stock Ticker

Clinuvel Spotlight

Company History

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide 16mg), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE...

Investors' Blog Posts

In 2010, Clinuvel announced that it would commence a clinical trial of a new drug for vitiligo. In late 2012 the first treatment results...

Clinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...

Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...

Related Webcasts

What can vitiligo patients do? - Lee Thomas and Dr ...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

The future of vitiligo treatment - Lee Thomas and D...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Vitiligo trials of SCENESSE® - Lee Thomas and Dr Ph...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Quick Links